Amyotrophic lateral sclerosis (ALS) is a degenerative disease related to the neuron system of the body. It is one of the category of motor neuron disease or MND. It is a category of various neurological disorders which are rare and are primarily involved in nerve cells and these cells look over the controlled movement of out voluntary muscles. This disease affects the motor neurons and the actions performed by them which results in the messages blockage between the muscles and brain fibers. Amyotrophic lateral sclerosis occurs due to gene mutation that is responsible for encoding the enzyme copper-zinc superoxide dismutase related to defect in the 9h chromosome and also the genetic inheritance of the person. Amyotrophic lateral sclerosis is observed in men more than in females. The abnormalities which are caused by genetic inheritance and also by gene mutation are capable of  resulting in the release of glutamate, which can further damage the motor neurons which are responsible for the controlling of  voluntary muscles. Symptoms observed commonly in an ALS patient include cramps, , spasticity, muscle weakness, respiratory problems, and fasciculation. It has been observed that the death rate is higher when the patient suffering from amyotrophic lateral sclerosis and it effects the respiratory cycle of the individuals by causing a failure in breathing.. ALS affects the functioning of diaphragm and also on the muscles of the chest. ALS doesn't affect your bladder control or other senses.

Market scope and structure analysis:

COVID-19 scenario analysis:

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicines supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as Hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are short of these drugs. Owing to the demand for vaccine and treatment drugs for COVID-19, the pharmaceutical and biotechnology industry is expected to witness a significant growth in the future.

Owing to such factors, COVID 19 is expected to have a significant impact on the Amyotrophic lateral sclerosis treatment market.

Top impacting factors: Market Scenario Analysis, Trends, Drivers and Impact Analysis

Increasing prevalence of amyotrophic lateral sclerosis disease, an inclination of population towards a stationary lifestyle, and increasing geriatric population are leading to an increase in demand for targeted and indicating treatment options, which are driving the global amyotrophic lateral sclerosis market. There has also been an evident growth in the geriatric population and awareness about ALS which are also driving the market growth.

On the other hand, the expensive  treatment of Amyotrophic lateral sclerosis, less awareness of amyotrophic lateral sclerosis disease, and  insubstantial treatment options are hampering the market growth.

New product launches to flourish the market:

On November 25, 2019, Mitsubishi Tanabe Pharma announced its third phase for its oral suspension of Edaravone which will be used to cure ALS treatment. On September 17th, 2019, they also announced its alliance with Daiichi Sankyo for Edaravone in Brazil.

On April 8th, 2020, IonisPharma established a $25,000 scholarship to help ALS patients in the greater San Diego area participate in physical and mental wellness programs.

On December 13, 2019, ITF Pharma announced FDA approval of supplemental new drug application for TIGLUTIK which is an oral suspension for the treatment of amyotrophic lateral sclerosis (ALS) with a Percutaneous Endoscopic Gastrostomy (PEG) feeding tube.

Surge in usage in hospital applications:

Amyotrophic lateral sclerosis medications are used in hospitals, specialty centers, research& academic institutes, among which hospital pharmacies are the highest consumers of the ALS treatment and are expected increase the demand further. There is a increasing preference in patients for hospital pharmacies and retail pharmacies. This can be accredited as  an easy and rapid way to a wide range of drugs and sufficient products offered by the distribution channels.

Key segments covered:

Key benefits of the report:

• This study presents the analytical depiction of the global Amyotrophic lateral sclerosis treatment industry along with the current trends and future estimations to determine the imminent investment pockets.
• The report presents information related to key drivers, restraints, and opportunities along with detailed analysis of the global Amyotrophic lateral sclerosis treatment market share.
• The current market is quantitatively analyzed from 2020 to 2027 to highlight the global Amyotrophic lateral sclerosis treatment market growth scenario.
• Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
• The report provides a detailed global Amyotrophic lateral sclerosis treatment market analysis based on competitive intensity and how the competition will take shape in coming years.

Questions answered in the Amyotrophic lateral sclerosis treatment Market research report:

• What are the leading market players active in the Amyotrophic lateral sclerosis treatment market
• What the current trends will influence the market in the next few years?
• What are the driving factors, restraints, and opportunities in the market?
• What are the projections for the future that would help in taking further strategic steps?

 Key Market Segments

 
Key Market Players

• Sun Pharmaceutical
• Mitsubishi Tanabe Pharma America
• Biogen
• Sanofi
• Mylan N.V.
• CovisPharma
• Ionis Pharmaceutical
• ITF Pharma
• Ascend Pharmaceuticals LLC
• Apotex Inc.